<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Paraneoplastic neurological syndromes.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Vedeler CA, Antoine JC, Giometto B, Graus F, Grisold W, Honnorat J, Sillevis Smitt PA, Verschuuren JJ, Voltz R, Paraneoplastic Neurological Syndrome Euronetwork. Paraneoplastic neurological syndromes. In: Gilhus NE, Barnes MP, Brainin M, editor(s). European handbook of neurological management. 2nd ed. Vol. 1. Oxford (UK): Wiley-Blackwell; 2011. p. 447-57. [92 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: Vedeler CA, Antoine JC, Giometto B, Graus F, Grisold W, Hart IK, Honnorat J, Sillevis Smitt PA, Verschuuren JJ, Voltz R, Paraneoplastic Neurological Syndrome Euronetwork. Management of paraneoplastic neurological syndromes: report of an EFNS Task Force. Eur J Neurol 2006 Jul;13(7):682-90.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Myasthenic syndromes in diseases classified elsewhere  (358.1); Other cerebral degeneration  (331.89); Polyneuropathy in malignant disease  (357.3); Unspecified causes of encephalitis, myelitis, and encephalomyelitis  (323.9); Unspecified disorders of nervous system  (349.9); Unspecified extrapyramidal disease and abnormal movement disorder  (333.90)"/><FieldValue Value="MSH: Fluorodeoxyglucose F18 ; Immunoglobulins, Intravenous ; Immunologic Tests ; Immunotherapy ; Lambert-Eaton Myasthenic Syndrome ; Limbic Encephalitis ; Nervous System Diseases ; Opsoclonus-Myoclonus Syndrome ; Paraneoplastic Cerebellar Degeneration ; Paraneoplastic Polyneuropathy ; Paraneoplastic Syndromes ; Paraneoplastic Syndromes, Nervous System ; Peripheral Nervous System Diseases ; Plasma Exchange ; Positron-Emission Tomography ; Referral and Consultation ; Sensation Disorders ; Serologic Tests ; Steroids ; Tomography Scanners, X-Ray Computed ; Tomography, X-Ray Computed "/><FieldValue Value="MTH: Computed Tomography Scanning Systems ; Extrapyramidal and movement disorders ; Fluorodeoxyglucose F18 ; follow-up ; Immunoglobulins, Intravenous ; Immunologic Tests ; Immunotherapy ; Lambert-Eaton Myasthenic Syndrome ; nervous system disorder ; Opsoclonus-Myoclonus Syndrome ; Paraneoplastic Syndromes, Nervous System ; Peripheral Neuropathy ; Plasma Exchange ; Positron-Emission Tomography ; Sensory neuropathy ; Serologic tests ; Steroids ; Unspecified cause of encephalitis, myelitis, and encephalomyelitis ; X-Ray Computed Tomography "/><FieldValue Value="PDQ: computed tomography ; fludeoxyglucose F 18 "/><FieldValue Value="SNOMEDCT_US: Cerebellar degeneration  (95646004); Computerized axial tomography  (77477000); Disorder of nervous system  (118940003); Disorder of the peripheral nervous system  (302226006); Disorder of the peripheral nervous system  (42658009); Eaton-Lambert syndrome  (56989000); Fluorodeoxyglucose F^18^  (35321007); Immunological therapy  (76334006); Intravenous immunoglobulin  (350344000); Limbic encephalitis  (230192003); Limbic encephalitis  (445014002); Myasthenic syndrome due to another disorder  (193209005); Neuronal antibody assay  (117916008); Opsoclonus-myoclonus syndrome  (230350000); Paraneoplastic cerebellar degeneration  (192877007); Paraneoplastic neuropathy  (21361000119109); Paraneoplastic neuropathy  (77659000); Paraneoplastic syndrome  (49783001); Plasma exchange  (19647005); Plasma exchange  (225067007); Positron emission tomography  (363678002); Positron emission tomography  (82918005); Positron emission tomography unit  (39821008); Positron emission tomography unit  (462323006); Sensory neuropathy  (95662005); Serologic test  (68793005); Steroid  (116566001)"/><FieldValue Value="SPN: SYSTEM, TOMOGRAPHY, COMPUTED, EMISSION ; SYSTEM, X-RAY, TOMOGRAPHY, COMPUTED "/><FieldValue Value="UMD: Scanning Systems, Computed Tomography  (13-469); Scanning Systems, Positron Emission Tomography  (16-375)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Paraneoplastic neurological syndromes (PNS):&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Limbic encephalitis &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Subacute sensory neuronopathy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Cerebellar degeneration &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Opsoclonus-myoclonus &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Lambert&amp;ndash;Eaton myasthenic syndrome &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Peripheral nerve hyperexcitability &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;strong&gt;Note&lt;/strong&gt;: Myasthenia gravis, paraproteinemic neuropathies, paraneoplastic retinopathy and dermatomyositis have not been included in this report.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Diagnosis" /><FieldValue Value="Evaluation" /><FieldValue Value="Management" /><FieldValue Value="Treatment" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Family Practice" /><FieldValue Value="Internal Medicine" /><FieldValue Value="Neurology" /><FieldValue Value="Oncology" /><FieldValue Value="Pediatrics" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Physicians" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;To outline guidelines for the management of classical paraneoplastic neurological syndromes (PNS)&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Patients with paraneoplastic neurological syndromes (PNS)&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Diagnosis/Evaluation&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;ol start=&quot;1&quot; style=&quot;list-style-type: decimal;&quot;&gt;&#xA;    &lt;li&gt;Assessment of onconeuronal antibodies&lt;/li&gt;&#xA;    &lt;li&gt;High-resolution computed tomography (CT) and fluorodeoxyglucose positron-emission tomography (FDG-PET)&lt;/li&gt;&#xA;    &lt;li&gt;Follow-up at regular intervals to search for tumors&lt;/li&gt;&#xA;&lt;/ol&gt;&#xA;&lt;p&gt;&lt;strong&gt;Management/Treatment&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;ol start=&quot;1&quot; style=&quot;list-style-type: decimal;&quot;&gt;&#xA;    &lt;li&gt;Treatment of underlying tumor&lt;/li&gt;&#xA;    &lt;li&gt;Specialist consultation&lt;/li&gt;&#xA;    &lt;li&gt;Immune therapy (steroids, plasma exchange, or intravenous immunoglobulin) for children with paraneoplastic opsoclonus myoclonus (POM) or adults with Lambert&amp;ndash;Eaton myasthenic syndrome (LEMS) or peripheral nerve hyperexcitability (PPNH)&lt;/li&gt;&#xA;    &lt;li&gt;Symptomatic therapy&lt;/li&gt;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;Sensitivity and specificity of diagnostic tests&lt;/li&gt;&#xA;    &lt;li&gt;Effectiveness of treatment&lt;/li&gt;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Search strategies have included English literature from the following databases: Cochrane Library, MedLine, PubMed (last search August 2009). The key words used for the search included 'limbic encephalitis', 'sensory neuronopathy' 'cerebellar ataxia', 'opsoclonus-myoclonus', 'Lambert&amp;ndash;Eaton myasthenic syndrome', 'neuromyotonia' in combination with 'investigation' and 'therapy'.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Evidence Classification Scheme for a Diagnostic Measure&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Class I&lt;/strong&gt;: A prospective study in a broad spectrum of persons with the suspected condition, using a 'gold standard' for case definition, where the test is applied in a blinded evaluation, and enabling the assessment of appropriate tests of diagnostic accuracy&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Class II&lt;/strong&gt;: A prospective study of a narrow spectrum of persons with the suspected condition, or a well-designed retrospective study of a broad spectrum of persons with an established condition (by 'gold standard') compared to a broad spectrum of controls, where test is applied in a blinded evaluation, and enabling the assessment of appropriate tests of diagnostic accuracy&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Class III&lt;/strong&gt;: Evidence provided by a retrospective study where either persons with the established condition or controls are of a narrow spectrum, and where test is applied in a blinded evaluation&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Class IV&lt;/strong&gt;: Any design where test is not applied in blinded evaluation OR evidence provided by expert opinion alone or in descriptive case series (without controls)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Evidence Classification Scheme for a Therapeutic Intervention&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Class I&lt;/strong&gt;: An adequately powered prospective, randomized, controlled clinical trial with masked outcome assessment in a representative population or an adequately powered systematic review of prospective randomized controlled clinical trials with masked outcome assessment in representative populations. The following are required:&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: lower-alpha;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Randomization concealment &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Primary outcome(s) is/are clearly defined &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Exclusion/inclusion criteria are clearly defined &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Adequate accounting for dropouts and crossovers with numbers sufficiently low to have minimal potential for bias &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Relevant baseline characteristics are presented and substantially equivalent among treatment groups or there is appropriate statistical adjustment for differences &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Class II&lt;/strong&gt;: Prospective matched-group cohort study in a representative population with masked outcome assessment that meets a&amp;ndash;e above or a randomized, controlled trial in a representative population that lacks one criteria a&amp;ndash;e&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Class III&lt;/strong&gt;: All other controlled trials (including well-defined natural history controls or patients serving as own controls) in a representative population, where outcome assessment is independent of patient treatment&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Class IV&lt;/strong&gt;: Evidence from uncontrolled studies, case series, case reports, or expert opinion&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Systematic Review" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;All evidence available was evaluated as Class IV &amp;ndash; case reports, case series and expert opinion (see the &quot;Rating Scheme for the Strength of the Evidence&quot; field). Thus no recommendations reach Level A, B or C. Good Practice Points were agreed by consensus (see the &quot;Rating Scheme for the Strength of the Recommendations&quot; field).&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Rating of Recommendations for a Diagnostic Measure&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Level A rating&lt;/strong&gt; (established as useful/predictive or not useful/predictive) requires at least one convincing class I study or at least two consistent, convincing class II studies.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Level B rating&lt;/strong&gt; (established as probably useful/predictive or not useful/predictive) requires at least one convincing class II study or overwhelming class III evidence.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Level C rating&lt;/strong&gt; (established as possibly useful/predictive or not useful/predictive) requires at least two convincing class III studies.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Rating of Recommendations for a Therapeutic Intervention&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Level A rating&lt;/strong&gt; (established as effective, ineffective, or harmful) requires at least one convincing class I study or at least two consistent, convincing class II studies.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Level B rating&lt;/strong&gt; (probably effective, ineffective, or harmful) requires at least one convincing class II study or overwhelming class III evidence.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Level C rating&lt;/strong&gt; (possibly effective, ineffective, or harmful) requires at least two convincing class III studies.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good Practice Point&lt;/strong&gt; Where there was lack of evidence but consensus was clear the task force members have stated their opinion as Good Practice Points.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A formal cost analysis was not performed and published cost analyses were not reviewed.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The guidelines were validated according to the European Federation of Neurological Societies (EFNS) criteria (see the &quot;Availability of Companion Documents&quot; field).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The levels of evidence (Class I-IV) supporting the recommendations and ratings of recommendations (A-C, Good Practice Points [GPP]) are defined at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Recommendations (GPP)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Patients with paraneoplastic neurological syndrome (PNS) most often present with neurological symptoms before an underlying tumour is detected. Onconeural antibodies should be sought in sera from patients with suspected PNS. The antibodies are important for diagnosis and tumour search. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Radiological investigations for tumours, such as high resolution computed tomography (CT) for the detection of small cell lung cancer (SCLC), are important, but should be followed by fluorodeoxyglucose positron-emission tomography (FDG-PET) if no tumour is found. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients should also be followed at regular intervals, for example every 6 months for up to 4 years, to search for tumour in cases where the initial tumour screen was negative. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Early detection and treatment of the tumour is the approach that offers the greatest chance for PNS stabilization. This should be done in cooperation with the oncologist, pulmonologist, gynaecologist or paediatrician depending on the associated tumour. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Immune therapy (steroids, plasma exchange, or intravenous immunoglobulin) usually has no or modest effect on paraneoplastic limbic encephalitis (PLE), subacute sensory neuropathy (SSN) or paraneoplastic cerebellar degeneration (PCD). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Children with paraneoplastic opsoclonus-myoclonus (POM) may respond to immune therapy, whereas no clear evidence of such therapy has been shown in adults with POM. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients with Lambert-Eaton myasthenic syndrome (LEMS) or paraneoplastic peripheral nerve hyperexcitability (PPNH) should be treated with immune therapy if symptomatic therapy does not give sufficient improvement. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Symptomatic therapy should be offered to all patients with PNS. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Definitions&lt;/span&gt;&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Evidence Classification Scheme for a Diagnostic Measure&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Class I&lt;/strong&gt;: A prospective study in a broad spectrum of persons with the suspected condition, using a 'gold standard' for case definition, where the test is applied in a blinded evaluation, and enabling the assessment of appropriate tests of diagnostic accuracy&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Class II&lt;/strong&gt;: A prospective study of a narrow spectrum of persons with the suspected condition, or a well-designed retrospective study of a broad spectrum of persons with an established condition (by 'gold standard') compared to a broad spectrum of controls, where test is applied in a blinded evaluation, and enabling the assessment of appropriate tests of diagnostic accuracy&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Class III&lt;/strong&gt;: Evidence provided by a retrospective study where either persons with the established condition or controls are of a narrow spectrum, and where test is applied in a blinded evaluation&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Class IV&lt;/strong&gt;: Any design where test is not applied in blinded evaluation OR evidence provided by expert opinion alone or in descriptive case series (without controls)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Evidence Classification Scheme for a Therapeutic Intervention&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Class I&lt;/strong&gt;: An adequately powered prospective, randomized, controlled clinical trial with masked outcome assessment in a representative population or an adequately powered systematic review of prospective randomized controlled clinical trials with masked outcome assessment in representative populations. The following are required:&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: lower-alpha;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Randomization concealment &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Primary outcome(s) is/are clearly defined &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Exclusion/inclusion criteria are clearly defined &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Adequate accounting for dropouts and crossovers with numbers sufficiently low to have minimal potential for bias &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Relevant baseline characteristics are presented and substantially equivalent among treatment groups or there is appropriate statistical adjustment for differences &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Class II&lt;/strong&gt;: Prospective matched-group cohort study in a representative population with masked outcome assessment that meets a&amp;ndash;e above or a randomized, controlled trial in a representative population that lacks one criteria a&amp;ndash;e&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Class III&lt;/strong&gt;: All other controlled trials (including well-defined natural history controls or patients serving as own controls) in a representative population, where outcome assessment is independent of patient treatment&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Class IV&lt;/strong&gt;: Evidence from uncontrolled studies, case series, case reports, or expert opinion&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Rating of Recommendations for a Diagnostic Measure&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Level A rating&lt;/strong&gt; (established as useful/predictive or not useful/predictive) requires at least one convincing class I study or at least two consistent, convincing class II studies.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Level B rating&lt;/strong&gt; (established as probably useful/predictive or not useful/predictive) requires at least one convincing class II study or overwhelming class III evidence.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Level C rating&lt;/strong&gt; (established as possibly useful/predictive or not useful/predictive) requires at least two convincing class III studies.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Rating of Recommendations for a Therapeutic Intervention&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Level A rating&lt;/strong&gt; (established as effective, ineffective, or harmful) requires at least one convincing class I study or at least two consistent, convincing class II studies.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Level B rating&lt;/strong&gt; (probably effective, ineffective, or harmful) requires at least one convincing class II study or overwhelming class III evidence.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Level C rating&lt;/strong&gt; (possibly effective, ineffective, or harmful) requires at least two convincing class III studies.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good Practice Point&lt;/strong&gt; Where there was lack of evidence but consensus was clear the task force members have stated their opinion as Good Practice Points.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None provided&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;All evidence available was evaluated as Class IV &amp;ndash; case reports, case series, and expert opinion. Thus, no recommendations reach Level A, B, or C . However, Good Practice Points (GPP) were agreed by consensus (see the &quot;Major Recommendations&quot; field).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Appropriate management of paraneoplastic neurological syndromes (PNS)&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This guideline provides the view of an expert task force appointed by the Scientific Committee of the European Federation of Neurological Societies (EFNS). It represents a peer-reviewed statement of minimum desirable standards for the guidance of practice based on the best available evidence. It is not intended to have legally binding implications in individual cases.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The European Federation of Neurological Societies has a mailing list and all guideline papers go to national societies, national ministries of health, World Health Organisation, European Union, and a number of other destinations. Corporate support is recruited to buy large numbers of reprints of the guideline papers and permission is given to sponsoring companies to distribute the guideline papers from their commercial channels, provided there is no advertising attached.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Getting Better" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Vedeler CA, Antoine JC, Giometto B, Graus F, Grisold W, Honnorat J, Sillevis Smitt PA, Verschuuren JJ, Voltz R, Paraneoplastic Neurological Syndrome Euronetwork. Paraneoplastic neurological syndromes. In: Gilhus NE, Barnes MP, Brainin M, editor(s). European handbook of neurological management. 2nd ed. Vol. 1. Oxford (UK): Wiley-Blackwell; 2011. p. 447-57. [92 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2006 Jul (revised 2011)" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="European Academy of Neurology - Medical Specialty Society" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;European Federation of Neurological Societies&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This study was supported by grant QLG1- T-2002-01756 of the European Commission.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;European Federation of Neurological Societies Task Force on Paraneoplastic Neurological Syndromes&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Task Force Members&lt;/em&gt;: C. A. Vedeler, Haukeland University Hospital and University of Bergen, Norway; J. C. Antoine, Hopital Bellevue, Saint Etienne, France; B. Giometto, University of Padua, Italy; F. Graus, Institut d'Investigacio Biomedica August Pi I Sunyer (IDIBAPS), Hospital Clinic, University of Barcelona, Spain; W. Grisold, Kaiser Franz Josef Hospital and Ludwig Boltzmann Institute for Neurooncology, Vienna, Austria; J. Honnorat, Hospital Neurologique, Lyon, France; P. A. E. Sillevis Smitt, Erasmus University Medical Center, Rotterdam, The Netherlands; J. J. G. M. Verschuuren, Leiden University Medical Center, The Netherlands; R. Voltz, University of Cologne, Germany&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The authors have reported no conflicts of interest relevant to this manuscript.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: Vedeler CA, Antoine JC, Giometto B, Graus F, Grisold W, Hart IK, Honnorat J, Sillevis Smitt PA, Verschuuren JJ, Voltz R, Paraneoplastic Neurological Syndrome Euronetwork. Management of paraneoplastic neurological syndromes: report of an EFNS Task Force. Eur J Neurol 2006 Jul;13(7):682-90.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://www.efns.org/fileadmin/user_upload/guidline_papers/EFNS_guideline_2011_Paraneoplastic_neurological_syndromes.pdf&quot; title=&quot;EFNS Web site&quot;&gt;European Federation of Neurological Societies (EFNS) Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following is available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Brainin M, Barnes M, Baron JC, Gilhus NE, Hughes R, Selmaj K, Waldemar G; Guideline Standards Subcommittee of the EFNS Scientific Committee. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces &amp;ndash; revised recommendations 2004. Eur J Neurol. 2004 Sep;11(9):577-81. Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://www.efns.org/fileadmin/user_upload/guidline_papers/EFNS_guideline_2004_neurological_management_guidelines.pdf&quot; title=&quot;European Federation of Neurological Societies Web site&quot;&gt;European Federation of Neurological Societies Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI on April 6, 2007. The information was verified by the guideline developer on May 15, 2007. This NGC summary was updated by ECRI Institute on February 20, 2012.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which is subject to the Blackwell-Synergy copyright restrictions.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouseâ„¢ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
